You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華潤雙鶴(600062.SH):2020年淨利降5%至10.05億元 擬10派2.9元
格隆匯 03-18 18:15

格隆匯3月18日丨華潤雙鶴(600062.SH)披露2020年年度報吿,報吿期內,公司實現營業收入85.04億元,同比下降9%;實現歸屬於上市公司股東的淨利潤10.05億元,同比下降5%;基本每股收益0.9635元,年報推10派2.90元(含税)。

慢病業務收入同比下降1%。雖然部分產品受到帶量採購影響,但非帶量採購的核心產品均有不錯的表現,降壓領域核心產品0號收入同比增長12%,重點產品復穗悦和硝苯地平緩釋片呈現雙位數增長;降糖藥糖適平收入同比增長10%;腦血管用藥諾百益(胞磷膽鹼鈉片)繼續保持高速增長,銷售收入增速23%。

專科業務收入同比增長1%。其中受疫情和出生率下降影響,兒科用藥領域收入同比下降7%,但核心產品珂立蘇和小兒氨基酸仍保持市場份額第一;腎科用藥領域收入同比增長11%,腹膜透析液保持增長,銷售收入同比增長11%;精神/神經領域銷售收入同比增長13%,丙戊酸鎂緩釋片銷售收入同比增長18%。

輸液業務受新冠肺炎疫情影響嚴重,收入同比下降16%。基本與行業表現相似,好於市場整體,市場份額穩定。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account